Analysts await Xtant Medical Holdings, Inc. (NASDAQ:XTNT) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.04 EPS, up 1050% or $0.42 from last year’s $-0.46 per share.

At the moment 5 analysts are watching Xtant Medical Holdings, Inc. (NASDAQ:XTNT), 2 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 3 analysts have a mean sales target of 24.04 million. For the quarter ending Jun-16, 3 analysts have a mean sales target of 24.85 million whilst for the year ending Dec-16, 3 analysts have a mean target of 100.97 million.

In terms of earnings per share, 2 analysts have a -0.37 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 2 analysts have a -0.22 EPS mean target and for the quarter ending Jun-16 there are 3 estimates of -0.97 EPS.

The biggest institutional shareholders in Xtant Medical Holdings, Inc. include Orbimed Advisors, LLC which owns 475 K million shares in the company valued at $1.33 million. Perkins Capital Management Inc is the second biggest holder with 423 K million shares currently valued at 1.18 million whilst Bard Associates Inc has 137 K million shares valued at 383.00 K million.

Total shares held by institutions as of the most recent company filings are 1,203,960 with a reported 0 bought and 0 sold. These holdings make up 10.13% of the company’s outstanding shares.

Currently insiders hold 5,083,864 shares in the business which makes up 42.77% of shares. The biggest holder currently is Guy S. Cook who owns 2,260,049 shares (19.01% of those outstanding), whilst Dr. David Kirschman holds 1,701,063 (14.31% of shares outstanding) and Mitchell Godfrey holds 711,467 (5.99% of shares outstanding).

The stock increased 13.75% or $0.42 during the last trading session, hitting $3.45. Xtant Medical Holdings, Inc. (NASDAQ:XTNT) has fallen 7.54% over the past 6 months and is downtrending.